Clinical studies and models have demonstrated that TH1902, by leveraging SORT1-mediated endocytosis, notably suppresses tumor growth more effectively than conventional chemotherapy agents like docetaxel alone, suggesting its potential as a targeted therapy for SORT1-positive gynecological cancers. This evidence concerns the gene SORT1 and neoplasm.